These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33091845)

  • 1. Pairing a prognostic target with potential therapeutic strategy for head and neck cancer.
    Lek SM; Li K; Tan QX; Shannon NB; Ng WH; Hendrikson J; Tan JWS; Lim HJ; Chen Y; Koh KKN; Skanthakumar T; Kwang XL; Chong FT; Leong HS; Tay G; Putri NE; Lim TKH; Hwang JSG; Ang MK; Tan DSW; Tan NC; Tan HK; Kon OL; Soo KC; Iyer NG; Ong CJ
    Oral Oncol; 2020 Dec; 111():105035. PubMed ID: 33091845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma.
    Li B; Zhu J; Meng L
    Mol Med Rep; 2019 Feb; 19(2):877-884. PubMed ID: 30535476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aurora-A signaling is activated in advanced stage of squamous cell carcinoma of head and neck cancer and requires osteopontin to stimulate invasive behavior.
    Chien CY; Tsai HT; Su LJ; Chuang HC; Shiu LY; Huang CC; Fang FM; Yu CC; Su HT; Chen CH
    Oncotarget; 2014 Apr; 5(8):2243-62. PubMed ID: 24810160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of AURKA as a Biomarker Associated with Cuproptosis and Ferroptosis in HNSCC.
    Jia X; Tian J; Fu Y; Wang Y; Yang Y; Zhang M; Yang C; Liu Y
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of CCT3 as a prognostic factor and correlates with cell survival and invasion of head and neck squamous cell carcinoma.
    Wang Y; Liu P; Zhang Z; Wang J; Cheng Z; Fan C
    Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34505628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
    Chen X; Cao Y; Sedhom W; Lu L; Liu Y; Wang H; Oka M; Bornstein S; Said S; Song J; Lu SL
    Mol Oncol; 2020 Jan; 14(1):139-158. PubMed ID: 31600013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
    Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
    Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.
    Mazumdar A; Henderson YC; El-Naggar AK; Sen S; Clayman GL
    Head Neck; 2009 May; 31(5):625-34. PubMed ID: 19107951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained Aurora Kinase B Expression Confers Resistance to PI3K Inhibition in Head and Neck Squamous Cell Carcinoma.
    Shah PA; Sambandam V; Fernandez AM; Zhao H; Mazumdar T; Shen L; Wang Q; Ahmed KM; Ghosh S; Frederick MJ; Wang J; Johnson FM
    Cancer Res; 2022 Dec; 82(23):4444-4456. PubMed ID: 36169922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant overexpression of transcription factor Forkhead box D1 predicts poor prognosis and promotes cancer progression in HNSCC.
    Li J; Yan T; Wu X; Ke X; Li X; Zhu Y; Yang J; Li Z
    BMC Cancer; 2021 Nov; 21(1):1205. PubMed ID: 34772357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism.
    Pickhard A; Siegl M; Baumann A; Huhn M; Wirth M; Reiter R; Rudelius M; Piontek G; Brockhoff G
    Oncotarget; 2014 Jul; 5(14):5428-38. PubMed ID: 24980817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELOVL6 promotes the progression of head and neck squamous cell carcinoma via activating WNT/β-catenin pathway.
    Wang R; Liu X; Li X; Qian M; Yang X; Jiang Q; Wang Y; Liu H; Chen J; Wang X; Gong L
    Mol Carcinog; 2024 Jun; 63(6):1079-1091. PubMed ID: 38426809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.
    Hanemaaijer SH; van Gijn SE; Oosting SF; Plaat BEC; Moek KL; Schuuring EM; van der Laan BFAM; Roodenburg JLN; van Vugt MATM; van der Vegt B; Fehrmann RSN
    Oral Oncol; 2018 May; 80():33-39. PubMed ID: 29706186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis.
    Lee K; Chang JW; Oh C; Liu L; Jung SN; Won HR; Kim YI; Rha KS; Koo BS
    Eur J Surg Oncol; 2020 Jun; 46(6):1066-1073. PubMed ID: 31864826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
    Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC.
    Liu J; Ouyang Y; Xia Z; Mai W; Song H; Zhou F; Shen L; Chen K; Li X; Zhuang SM; Liao J
    Cell Oncol (Dordr); 2024 Apr; 47(2):623-638. PubMed ID: 37856075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
    Radhakrishnan A; Nanjappa V; Raja R; Sathe G; Puttamallesh VN; Jain AP; Pinto SM; Balaji SA; Chavan S; Sahasrabuddhe NA; Mathur PP; Kumar MM; Prasad TS; Santosh V; Sukumar G; Califano JA; Rangarajan A; Sidransky D; Pandey A; Gowda H; Chatterjee A
    Sci Rep; 2016 Oct; 6():36132. PubMed ID: 27796319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.
    Chi LH; Chang WM; Chang YC; Chan YC; Tai CC; Leung KW; Chen CL; Wu AT; Lai TC; Li YJ; Hsiao M
    Sci Rep; 2017 Aug; 7(1):9031. PubMed ID: 28831179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
    Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
    Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.